Literature DB >> 33618521

Prognostic impact of GPR56 in patients with colorectal cancer.

Dae-Ro Lim1,2, Dong-Hyun Kang3, Jung-Chul Kuk1, Tae-Hyung Kim1, Eung-Jin Shin1, Tae-Sung Ahn3, Hyeong-Joo Kim4, Dong-Jun Jeong4, Moo-Jun Baek3, Nam-Kyu Kim2.   

Abstract

G protein-coupled receptor 56 (GPR56) belongs to the adhesion G protein-coupled receptor subfamily, which plays a role in cell progression and survival. The aim of this study was to investigate the role of the GPR56 gene in a cell line study and the impact of its protein expression on the prognosis of colorectal cancer (CRC) patients. The effect of GPR56 on tumor cell proliferation (WST-1 assay), invasion (Transwell assay), migration (Transwell assay, wound healing assay), and colony-forming ability (semisolid agar colony-forming assay) was explored. The expression levels of GPR56 in tissue samples of 109 CRC patients were evaluated by immunohistochemistry. The prognostic value of GRP56 was analyzed using univariate and multivariate analyses. The downregulation of GPR56 in the CRC cell line reduced cell proliferation as compared with that in a control sample (48 h; p=0.042, 72 h; p=0.001). Downregulation of the GPR56 expression reduced cell invasion and migration abilities and inhibited colony-forming abilities (p<0.005). The 5-year overall survival rate was worse in the high-expression group as compared with that in the low-expression group (51.6% vs. 74.4%, p=0.008). High GPR56 expression was a significant prognostic factor for overall survival of CRC patients in the univariate (p=0.001) and multivariate (p<0.001) analyses. The expression level of GPR56 plays an important role in tumor progression in CRC, and it may serve as a prognostic indicator in CRC patients.

Entities:  

Year:  2021        PMID: 33618521     DOI: 10.4149/neo_2021_201209N1333

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  2 in total

1.  The Novel Immune Checkpoint GPR56 Is Expressed on Tumor-Infiltrating Lymphocytes and Selectively Upregulated upon TCR Signaling.

Authors:  Vrouyr Bilemjian; Martijn R Vlaming; Jimena Álvarez Freile; Gerwin Huls; Marco De Bruyn; Edwin Bremer
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

Review 2.  Role of ADGRG1/GPR56 in Tumor Progression.

Authors:  Kwai-Fong Ng; Tse-Ching Chen; Martin Stacey; Hsi-Hsien Lin
Journal:  Cells       Date:  2021-11-29       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.